Last reviewed · How we verify
Gallium-68-tilmanocept
Gallium-68-tilmanocept is a Radiopharmaceutical; PET imaging agent Small molecule drug developed by UMC Utrecht. It is currently in Phase 3 development for PET imaging of infection and inflammation (phase 3 development), Potential oncology imaging applications for immune cell infiltration assessment. Also known as: 68Ga-tilmanocept.
Gallium-68-tilmanocept is a radioactive imaging agent that binds to mannose receptors on immune cells to visualize inflammation and infection sites.
Gallium-68-tilmanocept is a radioactive imaging agent that binds to mannose receptors on immune cells to visualize inflammation and infection sites. Used for PET imaging of infection and inflammation (phase 3 development), Potential oncology imaging applications for immune cell infiltration assessment.
At a glance
| Generic name | Gallium-68-tilmanocept |
|---|---|
| Also known as | 68Ga-tilmanocept |
| Sponsor | UMC Utrecht |
| Drug class | Radiopharmaceutical; PET imaging agent |
| Target | Mannose receptor (CD206) |
| Modality | Small molecule |
| Therapeutic area | Oncology; Infectious Disease; Inflammation Imaging |
| Phase | Phase 3 |
Mechanism of action
Tilmanocept is a small-molecule radiopharmaceutical labeled with Gallium-68, a positron-emitting isotope. It targets mannose receptors (CD206) expressed on activated macrophages and other immune cells, allowing PET imaging of inflammatory and infectious lesions. This enables non-invasive visualization and quantification of immune cell infiltration in various disease states.
Approved indications
- PET imaging of infection and inflammation (phase 3 development)
- Potential oncology imaging applications for immune cell infiltration assessment
Common side effects
- Radiation exposure (minimal from diagnostic dose)
- Injection site reactions
- Allergic reactions
Key clinical trials
- Feasibility of Gallium-68-tilmanocept PET/CT for Sentinel Lymph Node Detection in Endometrial Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gallium-68-tilmanocept CI brief — competitive landscape report
- Gallium-68-tilmanocept updates RSS · CI watch RSS
- UMC Utrecht portfolio CI
Frequently asked questions about Gallium-68-tilmanocept
What is Gallium-68-tilmanocept?
How does Gallium-68-tilmanocept work?
What is Gallium-68-tilmanocept used for?
Who makes Gallium-68-tilmanocept?
Is Gallium-68-tilmanocept also known as anything else?
What drug class is Gallium-68-tilmanocept in?
What development phase is Gallium-68-tilmanocept in?
What are the side effects of Gallium-68-tilmanocept?
What does Gallium-68-tilmanocept target?
Related
- Drug class: All Radiopharmaceutical; PET imaging agent drugs
- Target: All drugs targeting Mannose receptor (CD206)
- Manufacturer: UMC Utrecht — full pipeline
- Therapeutic area: All drugs in Oncology; Infectious Disease; Inflammation Imaging
- Indication: Drugs for PET imaging of infection and inflammation (phase 3 development)
- Indication: Drugs for Potential oncology imaging applications for immune cell infiltration assessment
- Also known as: 68Ga-tilmanocept
- Compare: Gallium-68-tilmanocept vs similar drugs
- Pricing: Gallium-68-tilmanocept cost, discount & access